Get notified when TYRA files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts
NASDAQ: TYRA Tyra Biosciences, Inc. 8-K

Tyra Biosciences completes routine annual meeting, elects three directors for 2026-2029 term

Filed June 2, 2026 · Period ending May 28, 2026 · ~1 min read

Key Changes

  • low

    Three Class II directors elected to three-year terms expiring 2029: Habib J. Dable, Susan Moran M.D., and Robert More, all receiving strong shareholder support with 41-44.5 million votes in favor.

  • low

    Shareholders ratified Ernst & Young LLP as independent auditor for fiscal 2026 with overwhelming approval (53 million votes for, minimal opposition).

This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (PXED 10-Q) is open in full — no account needed.

Partner

Trade TYRA commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?

Source-verified from EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify